MedPath

The frontotemporal syndrome in amyotrophic lateral sclerosis: screen, impact, imaging and pathology.

Completed
Conditions
binnen zenuwstelsel aandoeningen: dementie van het frontotemporale type (FTD)
amyotrophic lateral sclerosis (ALS)
Motor neuron disease (MND)
10029317
Registration Number
NL-OMON44137
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
181
Inclusion Criteria

Age >= 18 years, speak Dutch fluently, have a proxy (partner, family member or close friend) who speaks Dutch fluently and is willing to fill in the questionnaires.
Furthermore, ALS patients must have sporadic or familial (fALS), probable, probable-laboratory supported or definite ALS, as defined by the El Escorial criteria, with a symptom duration of less than 12 months. ALS-FTD and behaviour variant-FTD patients must have sporadic or familial, probable or definite bv-FTD, as defined by the Neary criteria and the revised criteria by Rascovsky et al.

Exclusion Criteria

Any neurological or psychiatric condition with cognitive impairment or behavioural changes, use of psychopharmaca, excessive alcohol intake, i.e. >= 5 drinks per day, forced vital capacity < 70% of the predicted value in the upright position, at the time of inclusion (ALS patients), incapacitated person.

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>1. A validated, short cognitive screening instrument for ALS patients.<br /><br>2. Differences in structural and functional brain networks (connectivity<br /><br>measures) between patients with and without a frontotemporal syndrome.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>1. An estimate of the impact of ALS and the frontotemporal syndrome on the<br /><br>patient and their carers.<br /><br>2. A brainbank of phenotyped ALS patients.</p><br>
© Copyright 2025. All Rights Reserved by MedPath